c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
GlobeNewswire Inc. | Nov 5, 2026 4:07 PM EST
Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04)
Read original article